미국의 정맥주사액 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 영양별, 최종 용도별, 부문별 예측(2025-2030년)

U.S. Intravenous Solutions Market Growth & Trends:

The U.S. intravenous solutions market size is anticipated to reach USD 7.91 billion by 2030 and is projected to grow at a CAGR of 7.8% during the forecast period, according to a new report by Grand View Research, Inc. The market is experiencing growth due to the increasing prevalence of disease and a rise in surgical procedures. The aging population, which is more prone to non-communicable diseases such as cancer, neurological, cardiovascular disorders, and spinal injuries, is also driving market expansion. In October 2024, Fresenius Medical Care announced initiatives to mitigate disruptions in dialysis care. The company is enhancing the production of PD and IV solutions by leveraging its global production facilities. Prompted by the Department of Health & Human Services, Fresenius Medical Care is committed to meeting the demand for IV fluids and peritoneal dialysis (PD) products through improved production strategies.

IV hydration therapy effectively treats severe dehydration, especially in people with chronic conditions like diabetes or kidney diseases, by replenishing the body's electrolyte balance. The primary treatment is saline solution, water mixed with sodium chloride. Solutions with sugars like glucose, dextrose, or levulose are also standard. In December 2023, Baxter, a prominent company in infusion therapies and technologies, finished the first stage of its IV bag recycling trial in partnership with Northwestern Medicine. This program has successfully diverted over six tons of PVC IV bag material from being disposed of in landfills. If these bags were placed end to end, they would stretch across Chicago, demonstrating the project's contribution to environmental preservation.

U.S. Intravenous Solutions Market Report Highlights:

• The total parenteral nutrition (TPN) type segment held the largest revenue share of 67.14% in 2024 due to its critical role in providing essential nutrients directly into the bloodstream for patients who cannot consume food orally or absorb nutrients through their gastrointestinal tract.
• Based on nutrients, the single-dose amino acid solution segment dominated the segment with a market share of 31.33% in 2024 as it offers a convenient and effective means of delivering protein directly to patients. These solutions are tailored to specific patient needs, ensuring that they receive adequate amino acids necessary for recovery and maintenance of bodily functions.
• The vitamins & minerals segment is expected to grow at the fastest CAGR over the forecast period. These micronutrients are essential for various metabolic processes and overall health, particularly in patients receiving TPN or other forms of parenteral nutrition.
• In terms of end use, the hospitals segment dominated the segment with a market share of 46.0% in 2024 due to their critical role in acute care settings. Hospitals require a steady supply of intravenous solutions for various medical procedures, including surgeries and emergency care, making them essential players in this market.
• The home segment is expected to grow at the fastest CAGR over the forecast period due to an increasing preference for at-home treatments, which are more convenient and cost-effective for patients.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Nutrients
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Nutrients' outlook
  • 2.2.3. End use outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Intravenous Solutions Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Aging population
    • 3.2.1.3. Advancements in medical technology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High costs associated with IV therapy due to shortages
    • 3.2.2.2. Risk of complications
• 3.3. U.S. Intravenous Solutions Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. U.S. Intravenous Solutions Market: Product Estimates & Trend Analysis

• 4.1. Global U.S. Intravenous Solutions Market: Product Dashboard
• 4.2. Global U.S. Intravenous Solutions Market: Product Movement Analysis
• 4.3. Global U.S. Intravenous Solutions Market by Product, Revenue
• 4.4. Total Parenteral Nutrition (TPN)
  • 4.4.1. Total parenteral nutrition (TPN) market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Peripheral Parenteral Nutrition (PPN)
  • 4.5.1. Peripheral parenteral nutrition (PPN) market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. U.S. Intravenous Solutions Market: Nutrients Estimates & Trend Analysis

• 5.1. Global U.S. Intravenous Solutions Market: Nutrients Dashboard
• 5.2. Global U.S. Intravenous Solutions Market: Nutrients Movement Analysis
• 5.3. Global U.S. Intravenous Solutions Market by Nutrients, Revenue
• 5.4. Carbohydrates
  • 5.4.1. Carbohydrates market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Single Dose Amino Acids
  • 5.5.1. Single dose amino acids market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Vitamins And Minerals
  • 5.6.1. Vitamins and minerals market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.7. Parenteral Lipid Emulsion
  • 5.7.1. Parenteral lipid emulsion market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.8. Others
  • 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. U.S. Intravenous Solutions Market: End Use Estimates & Trend Analysis

• 6.1. Global U.S. Intravenous Solutions Market: End Use Dashboard
• 6.2. Global U.S. Intravenous Solutions Market: End Use Movement Analysis
• 6.3. Global U.S. Intravenous Solutions Market by End Use, Revenue
• 6.4. Home
  • 6.4.1. Home market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Hospitals
  • 6.5.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Infusion Center
  • 6.6.1. Infusion center market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Fresenius Kabi AG
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Pfizer Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Baxter
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. B. Braun Melsungen AG
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. JW Life Science
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. ICU Medical, Inc.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Grifols USA, LLC
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Amphastar Pharmaceuticals, Inc.
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Athenex, Inc.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Rockwell Medical, Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Exela Pharma Sciences, LLC
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives